2025 Annual Board of Directors Work Report
In 2025, the Board of Directors of Hubei Hendi Pharmaceutical Co., Ltd. strictly adhered to the Company Law, Securities Law, Shenzhen Stock Exchange GEM Listing Rules, and relevant regulations, fulfilling its responsibilities as entrusted by the shareholders' meeting and diligently carrying out various tasks to promote the company's sustainable and stable development. The following is a report on the board's work in 2025:
1. Company Operating Conditions in 2025
In 2025, facing a complex and changing pharmaceutical industry environment, increasing market competition, and ongoing policy adjustments, the company focused on its annual operational goals, adhering to the business philosophy of "Scientific Enterprise, Healthy Life." The company steadily advanced the collaborative development strategy of raw materials and formulations, continuously optimized production and operational management, increased R&D innovation and market expansion efforts, and solidly promoted the implementation of key tasks.
1.1 Performance Completion
In 2025, the company invested 28,793,641.91 yuan in R&D, including 25,180,041.91 yuan in R&D expenses and 3,613,600.00 yuan in development expenditures, a decrease of 12.58% compared to the same period last year. The company obtained national drug registration certificates for products including ibuprofen sustained-release capsules (0.3g), torasemide injection (2ml: 10mg/4ml: 20mg), ibuprofen suspension (30ml: 0.6g; 100ml: 2g), and febuxostat tablets (20mg, 40mg). The applications for the market launch of arginine ibuprofen raw materials and metoclopramide raw materials were approved, and several products, including abiraterone acetate tablets (0.25g, 0.5g), arginine ibuprofen granules (0.2g, 0.4g), atropine sulfate injection (0.5mg/1ml), and ibuprofen injection (800mg/8ml, 800mg/200ml), are under research with smooth project progress.
In 2025, the company achieved operating revenue of 453,306,981.13 yuan, an increase of 1.67% compared to the same period last year, while the net profit attributable to shareholders of the listed company was 34,910,598.79 yuan, a decrease of 61.87% compared to the same period last year. The company actively promoted the integration of "raw materials + formulations," and with the successive approval and market launch of new formulation products, the sales revenue from formulations reached 107,461,500.31 yuan, breaking the 100 million yuan mark again, with a year-on-year growth of 26.11%. The company filed two patents, one for a preparation method of dexmedetomidine and another for a method for detecting potassium ion content in azilsartan potassium and its application, both of which have entered the substantive examination stage.
In 2025, the company's wholly-owned subsidiary, Wuhan Baike Pharmaceutical, underwent a cGMP (current Good Manufacturing Practice) on-site inspection by the U.S. Food and Drug Administration (FDA) and received the FDA's inspection report. The company received a "High-tech Enterprise Certificate" jointly issued by the Hubei Provincial Department of Science and Technology, Hubei Provincial Department of Finance, and the State Taxation Administration Hubei Provincial Tax Service, certificate number: GR202442001598, marking the company's re-recognition as a high-tech enterprise after the expiration of its previous certificate. In 2025, the company actively promoted the implementation of fundraising projects. The safety and environmental upgrade project for the ibuprofen raw material hydrolysis and acidification position passed the joint acceptance by the construction department and has officially been put into use after trial production. The high-end pharmaceutical formulation internationalization project obtained the construction engineering permit on June 5, 2025, and is currently in the civil construction phase.